Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Nov 27;320(20):2149-2151.
doi: 10.1001/jama.2018.12358.

Trends in First Gabapentin and Pregabalin Prescriptions in Primary Care in the United Kingdom, 1993-2017

François Montastruc  1 , Simone Y Loo  2 , Christel Renoux  2
Affiliations

Trends in First Gabapentin and Pregabalin Prescriptions in Primary Care in the United Kingdom, 1993-2017

François Montastruc et al. JAMA. .

Erratum in

  • Incomplete Funding.
    [No authors listed] [No authors listed] JAMA. 2019 Feb 19;321(7):709. doi: 10.1001/jama.2019.0152. JAMA. 2019. PMID: 30778582 No abstract available.
  • Error in the Introduction.
    [No authors listed] [No authors listed] JAMA. 2019 Apr 23;321(16):1636. doi: 10.1001/jama.2019.3897. JAMA. 2019. PMID: 31012908 Free PMC article. No abstract available.

Abstract

This study examined the rates of patients in the United Kingdom treated with gabapentin and pregabalin for the first time, and the rates of these patients with an off-label indication or a coprescription of opioids or benzodiazepines.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.

Figures

Figure 1.
Figure 1.. New Users of Gabapentin and Pregabalin in the UK Primary Care System from 1993 to 2017a
Rates of new users of gabapentin (A) and pregabalin (B) in the UK primary care system documented in the Clinical Practice Research Datalink from 1993 to 2017. aGabapentin and pregabalin were licensed in United Kingdom in 1993 and 2004, respectively.
Figure 2.
Figure 2.. New Users With a Gabapentin and Pregabalin Indicationa in the UK Primary Care System From 1993 to 2017b
Rates of new users with an identified gabapentin and pregabalin indication in the UK Clinical Practice Research Datalink from 1993 to 2017. aApproved gabapentinoid indications in the United Kingdom include epilepsy, neuropathic pain, migraines (gabapentin), and generalized anxiety disorder (pregabalin). Off-label indications were defined as nonneuropathic pain, migraines (pregabalin), generalized anxiety disorder (gabapentin), fibromyalgia, substance withdrawal, and others (eg, psychiatric disease, tremor, restless legs syndrome). bPatients for whom a prescription indication could not be identified were not included.
See this image and copyright information in PMC

References

    1. Johansen ME. Gabapentinoid use in the United States 2002 Through 2015. JAMA Intern Med. 2018;178(2):292-294. doi:10.1001/jamainternmed.2017.7856 - DOI - PMC - PubMed
    1. Goodman CW, Brett AS. Gabapentin and Pregabalin for Pain - Is Increased Prescribing a Cause for Concern? N Engl J Med. 2017;377(5):411-414. doi:10.1056/NEJMp1704633 - DOI - PubMed
    1. Gomes T, Juurlink DN, Antoniou T, Mamdani MM, Paterson JM, van den Brink W. Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case-control study. PLoS Med. 2017;14(10):e1002396. doi:10.1371/journal.pmed.1002396 - DOI - PMC - PubMed
    1. Iacobucci G. UK government to reclassify pregabalin and gabapentin after rise in deaths. BMJ. 2017;358:j4441. doi:10.1136/bmj.j4441 - DOI - PubMed
    1. Herrett E, Gallagher AM, Bhaskaran K, et al. . Data Resource Profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol. 2015;44(3):827-836. doi:10.1093/ije/dyv098 - DOI - PMC - PubMed

MeSH terms